Iris A Bermejo, Ana Guerreiro, Ander Eguskiza, Nuria Martínez-Sáez, Foivos S Lazaris, Alicia Asín, Víctor J Somovilla, Ismael Compañón, Tom K Raju, Srdan Tadic, Pablo Garrido, Josune García-Sanmartín, Vincenzo Mangini, Ana S Grosso, Filipa Marcelo, Alberto Avenoza, Jesús H Busto, Fayna García-Martín, Ramón Hurtado-Guerrero, Jesús M Peregrina, Gonçalo J L Bernardes, Alfredo Martínez, Roberto Fiammengo, Francisco Corzana
Mucin-1 (MUC1) glycopeptides are exceptional candidates for potential cancer vaccines. However, their autoantigenic nature often results in a weak immune response. To overcome this drawback, we carefully engineered synthetic antigens with precise chemical modifications. To be effective and stimulate an anti-MUC1 response, artificial antigens must mimic the conformational dynamics of natural antigens in solution and have an equivalent or higher binding affinity to anti-MUC1 antibodies than their natural counterparts...
January 22, 2024: JACS Au